SMAD7 and neoplasm: Passarelli M.N. et al. (2011) [32] found that SMAD7 variants that inhibit TGFβ completely may reduce its tumor suppressor activity (resulting in an increased risk), but can also reduce their ability to promote their metastatic promoter activity (resulting in a slower progression of the tumor and improved survival) [32].